Minimum investment
$100k
Offering size
$40.5M
How much has sold
100.0%
Asset type
Life sciences (CDMO / lab-office) property
Location
Philadelphia, Pennsylvania
Financing
Leveraged. This offering reports mortgage debt on the property.
Sponsor-reported, from SEC filings and cited sources.
What is this, in one paragraph?
two life sciences industrial properties combines the historical SEC filing record with the cited public sources we found for the property and its outcome. Use the chapters below to see what those sources establish, then use the source list to check the underlying materials.
Show sources (1)Hide sources (1)
These links support the historical public record; individual details may come from different sources.
On a 45-day clock? Find day 45 and day 180 from the sale date, then come back to this record.
What exactly is the property?
- Reported location
- Philadelphia, Pennsylvania
- Property size
- two separate properties; nearly 18 acres; more than 250,000 square feet of interior space
How did it end?
No sale or other ending on record
Latest direct evidence supports continued operation: NexPoint's March 31, 2026 SEC Form 10-Q states that NexPoint Life Sciences II DST owns a Philadelphia manufacturing and production facility under a triple-net lease, while NexPoint's March 31, 2026 DST page reports three full-cycle DSTs but lists Life Sciences III—not II—as the current life-sciences offering; the sponsor's December 18, 2025 release describes Life Sciences II only as fully subscribed.
two separate properties; nearly 18 acres; more than 250,000 square feet of interior space
Supporting evidence
How is it financed, and what does it pay?
- Financing
- Leveraged. This offering reports mortgage debt on the property.
Who's behind it?
- Sponsor
- NexPoint
- Legal Trust name
- NexPoint Life Sciences II DST
- May convert to a REIT
- No
- Offerings from this sponsor
- 6 active / 17 total offerings from NexPoint
Reported by the sponsor. Top1031 does not independently audit sponsor-reported figures.
What does the paperwork say?
- First Form D filedThe public offering record begins.
- Offering amount recordedA Form D amendment recorded offering and sales totals.
- Filing record updatedA later amendment updated the sponsor’s filing record.
- Latest Form D filedThe most recent sponsor-filed checkpoint in this record.
- Filings on record
- 19
- How it may be offered
- Rule 506(c)May be advertised publicly. Every buyer’s accredited status must be verified.
- Source filing
- Read the filings on SEC EDGAR
A Form D is the notice a sponsor files when it starts raising money. A Form D filing does not mean the SEC approved, endorsed, or verified the offering.
DST interests are illiquid private securities. You may lose some or all of your investment. Distributions, tax treatment, and exit timing are not guaranteed. Review the current Private Placement Memorandum before investing.
Common questions
What happened to two life sciences industrial properties?
Top1031 lists two life sciences industrial properties as historical. It is no longer raising money.
Where does Top1031 get the data for two life sciences industrial properties?
Top1031 builds this record from the sponsor’s own SEC filings and cited sponsor disclosures. Filings can lag what is happening now. A Form D filing does not mean the SEC approved, endorsed, or verified the offering.
Chapter 8NexPoint Fully Subscribes $42 Million Life Science II DSTPR Newswire syndication of NexPoint's announcement that the NexPoint Life Science II DST has reached its $42 million equity raise target since launch. NexPoint Announces Co-investment in NexPoint Life Sciences II DSTNexPoint discloses 6% initial co-investment (target 10-12%) in the II DST, reaffirming the two Philadelphia properties occupied by a subsidiary of Adare Pharmaceuticals. NexPoint Expands Life Sciences Real Estate Footprint with Acquisition of Two Properties from Adare Pharma SolutionsMirror of NexPoint press release confirming Philadelphia acquisition and $42M raise target. NexPoint Acquires Life Science Properties in PhiladelphiaTrade-press coverage of NexPoint's Philadelphia life-sciences acquisition via the II DST and sale-leaseback around Frontida Biopharm. Northeast Philadelphia pharmaceutical plants sell to Texas buyerRecords show NexPoint acquired four parcels on the 1000 and 1100 blocks of Orthodox Street in Juniata Park from Frontida.